Advancing Cell and Gene Therapy Development Through Strategic Bioanalysis
Cell and gene therapy programs require analytical strategies that can address complex biology, evolving development requirements, and increasingly sophisticated therapeutic modalities. Bioanalysis plays an important role in generating the data needed to understand these therapies and support development decisions from early discovery through clinical development.
Smithers has extensive experience supporting complex drug development programs through bioanalytical services, including molecular biology and immunogenicity capabilities. Smithers will bring this expertise to the Cell & Gene Meeting on the Mesa, taking place October 5–7 in Phoenix, Arizona. Christina Satterwhite, President, and Agostinho G. Rocha, Site Director of Smithers Pharmaceutical Development Services, will represent Smithers throughout the conference.
The Cell & Gene Meeting on the Mesa brings together leaders across the cell and gene therapy industry for scientific discussions, partnering meetings, company presentations, and networking. The 2026 event is expected to bring together more than 1,500 leaders and host more than 5,000 partnering meetings.
Cell and Gene Therapy Requires a Specialized Bioanalytical Strategy
Cell and gene therapies can present analytical challenges that differ substantially from traditional pharmaceutical development programs. The biological complexity of these therapies can require specialized approaches to characterize responses, evaluate treatment effects, and generate data that support development decisions.
Bioanalysis therefore needs to extend beyond individual assays. The analytical strategy must consider the biology of the therapy, the development stage, the questions the program needs to answer, and how the resulting data will be used.
Smithers supports bioanalytical drug development across phases and therapeutic modalities, with services that include assay development, validation, and sample analysis. Its laboratories operate under GLP and GCP requirements, supporting the generation of reliable data for pharmaceutical development programs.
Molecular Biology and Immunogenicity Support Complex Programs
Cell and gene therapy programs can require expertise across multiple areas of bioanalysis. Molecular biology is particularly relevant to gene therapy programs, while immunogenicity testing can be an important consideration when evaluating the biological response to a therapeutic.
The analytical requirements can also vary significantly depending on the modality and development stage. Programs involving gene therapies, engineered cell therapies, and emerging approaches such as in vivo CAR-T can create distinct analytical questions that require appropriately designed methods and experienced scientific oversight. Molecular approaches such as qPCR and ddPCR can provide important tools for generating and analyzing data across cell and gene therapy development.
Smithers applies multidisciplinary scientific expertise to these programs. This approach allows bioanalytical considerations to be evaluated within the broader biological context rather than treating analytical testing as an isolated development activity.
Bioanalysis Should Support Development Decisions
The value of bioanalysis extends beyond generating test results. Analytical data must provide meaningful information that supports decisions throughout development.
Early-stage programs may require analytical approaches that help characterize a developing therapeutic and establish an appropriate testing strategy. As programs progress, assay requirements can evolve alongside clinical objectives, regulatory expectations, and the need for increasingly robust data.
A bioanalytical strategy established early can also help identify potential analytical challenges before they affect later development activities. Method performance, sample requirements, assay sensitivity, and other considerations can be addressed as the program develops rather than after problems emerge.
Smithers provides bioanalytical support across drug development phases and modalities, with tailored solutions designed around the requirements of individual programs.
A Multidisciplinary Approach Can Help Resolve Complex Bioanalytical Challenges
Cell and gene therapy development rarely fits within a single scientific discipline. Complex programs can require collaboration among specialists with expertise in molecular biology, immunogenicity, assay development, validation, and related areas of bioanalysis.
That multidisciplinary perspective can become particularly important when a program encounters unexpected analytical results or other development challenges. Resolving those issues requires more than identifying whether an assay produced an acceptable result. It requires understanding the underlying biology, determining why the result occurred, and identifying an analytical approach that can provide scientifically meaningful data.
Smithers' bioanalytical team brings together scientific expertise to develop and execute solutions for complex drug development programs. Its bioanalytical services are designed to support programs from discovery through product launch while maintaining a focus on accuracy, compliance, and program-specific requirements.
Partnerships Can Accelerate Cell and Gene Therapy Development
Selecting a bioanalytical partner is an important consideration for sponsors developing cell and gene therapies. Scientific expertise matters, but so does the ability to work collaboratively as program requirements evolve.
Effective collaboration allows the bioanalytical team to understand the therapeutic, the development objectives, and the specific challenges facing the program. It also creates an opportunity to identify potential analytical issues early and develop solutions that align with the sponsor's broader development strategy.
For Smithers, that collaborative approach is central to conversations with current and prospective clients. Each program brings different scientific questions and development priorities. Understanding those priorities is the first step toward determining how Smithers' bioanalytical capabilities can support the program.
Staying Current With Cell and Gene Therapy Innovation
Cell and gene therapy continues to evolve, with new therapeutic approaches creating new analytical requirements. Emerging modalities, including in vivo CAR-T approaches, demonstrate how quickly the field is expanding beyond established development models.
Maintaining an understanding of these developments is important for bioanalytical organizations supporting sponsors in this space. Industry conferences provide an opportunity to engage directly with developers, understand the challenges emerging across programs, and stay informed about new technologies and approaches.
The Cell & Gene Meeting on the Mesa provides that opportunity through expert-led panels, workshops, company presentations, and partnering meetings focused on developments across the cell and gene therapy industry.
Connect With Smithers at the Cell & Gene Meeting on the Mesa
Smithers will attend the Cell & Gene Meeting on the Mesa in Phoenix from October 5–7 to connect with current clients, prospective sponsors, and organizations developing the next generation of cell and gene therapies.
Christina Satterwhite and Agostinho G. Rocha will be available throughout the conference to discuss bioanalytical challenges, molecular biology, immunogenicity, assay development, and the analytical needs associated with complex cell and gene therapy programs.
Sponsors developing gene therapy, cell therapy, or emerging modalities such as in vivo CAR-T can schedule time with Smithers to discuss their programs and identify opportunities for scientific collaboration. Conversations can focus on the specific analytical challenges a program is facing and how Smithers' multidisciplinary bioanalytical expertise can support development from discovery through later stages.
Schedule a meeting with Smithers at the Cell & Gene Meeting on the Mesa to discuss a cell or gene therapy program and explore how Smithers can support its bioanalytical development needs
